hexahydroxydiphenic acid | 128785-08-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 单宁
• 英文名称: hexahydroxydiphenic acid
• 英文别名: diphenic acid；4,4',5,5',6,6'-hexahydroxydiphenic acid；(+/-)-4,5,6,4',5',6'-hexahydroxy-diphenic acid；(+/-)-4,5,6,4',5',6'-Hexahydroxy-diphensaeure；2-(6-carboxy-2,3,4-trihydroxyphenyl)-3,4,5-trihydroxybenzoic acid
• CAS: 128785-08-0
• 化学式: C₁₄H₁₀O₁₀
• 分子量: 338.227
• InChiKey: MFTSECOLKFLUSD-UHFFFAOYSA-N

物化性质

• 沸点：
  686.3±55.0 °C(Predicted)
• 密度：
  1.985±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  196
• 氢给体数：
  8
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  hexahydroxydiphenic acid 、 碘甲烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以5.07 g的产率得到dimethyl (S)-4,4',5,5',6,6'-hexamethoxydiphenoate
  参考文献：
  名称：

  联芳基二面角的微调：通过X射线晶体学分析五个同源的三原子桥联苯的结构特征。

  摘要：

  包含5,7-二氢-1,2,3,9,10,11-六甲氧基二苯并[c，e]奥西平，6,7-二氢-1,2,3,9， 10,11-六甲氧基-6-甲基-5H-二苯并[c，e] a嗪，5,7-二氢-1,2,3,9,10,11-六甲氧基二苯并[c，e]噻吩和6 X射线晶体结构分析已表征了后者的-氧化物和6，6-二氧化物衍生物。在该系列中，环内和环外联芳基二面角在10度范围内变化，反映了分子内（空间，几何）和分子间（晶体堆积）力的变化平衡，前者是微调联芳基螺旋度的潜在控制元素系统。

  DOI：

  10.1107/s0108768105006713
• 作为产物：
  描述：

  鞣花酸 在 氢氧化钾 、 四丁基碘化铵 、 硫酸二甲酯 作用下， 以 水 为溶剂， 反应 12.0h， 以8 g的产率得到hexahydroxydiphenic acid
  参考文献：
  名称：

  联芳基二面角的微调：通过X射线晶体学分析五个同源的三原子桥联苯的结构特征。

  摘要：

  包含5,7-二氢-1,2,3,9,10,11-六甲氧基二苯并[c，e]奥西平，6,7-二氢-1,2,3,9， 10,11-六甲氧基-6-甲基-5H-二苯并[c，e] a嗪，5,7-二氢-1,2,3,9,10,11-六甲氧基二苯并[c，e]噻吩和6 X射线晶体结构分析已表征了后者的-氧化物和6，6-二氧化物衍生物。在该系列中，环内和环外联芳基二面角在10度范围内变化，反映了分子内（空间，几何）和分子间（晶体堆积）力的变化平衡，前者是微调联芳基螺旋度的潜在控制元素系统。

  DOI：

  10.1107/s0108768105006713

文献信息

• Ellagitannin biosynthesis: oxidation of pentagalloylglucose to tellimagrandin II by an enzyme from Tellima grandiflora leaves
  作者：Ruth Niemetz、Georg G. Gross、Gerhard Schilling

  DOI：10.1039/b006270g

  日期：——

  First evidence of the in vitro oxidation of 1,2,3,4,6-pentagalloylglucose to the ellagitannins, tellimagrandin II and 1,4,6-tri-O-galloyl-2,3-O-hexahydroxydiphenoyl-β- D-glucose, has been obtained with a partially purified enzyme from leaves of Tellima grandiflora (fringe cups, Saxifragaceae).

  首次获得了体外氧化1,2,3,4,6-五羟基没食子酸葡萄糖为椭圆单宁的证据，包括特利玛格林 II 和 1,4,6-三-O-羟基-2,3-O-六羟基二苯酚-β-D-葡萄糖，使用的是从特利玛 grandiflora（边缘杯，虎耳草科）叶子中部分纯化的酶。
• [EN] PHOSPHORYLATED POLYPHENOLS AS COLOUR-STABLE AGENTS<br/>[FR] POLYPHENOLS PHOSPHORYLES UTILISES COMME AGENTS DE COULEUR STABLE
  申请人：AJINOMOTO OMNICHEM S A

  公开号：WO2006029483A1

  公开（公告）日：2006-03-23

  The present invention relates to phosphorylated polyphenols, preferably tannins that, unlike their unphosphorylated counterparts, do not suffer from relatively low stability, resulting in an activity that is relatively short in time, and/or that do not result in yellowing of materials therewith such as textiles or polymers. The present invention further relates to a simple, cheap and environmentally friendly way of preparing these compounds. The phosphorylation process of the invention can be extended to simple phenolic compounds as well, as long as these have at least one accessible hydroxyl group. The phosphorylated compounds according to the invention can be used as antioxidants, as radical scavengers, as complexating agents for metals and proteins, as antibacterials or antiallergenic compounds, and as agents to flock textile.

  本发明涉及磷酸化多酚，优选为单宁，与其未磷酸化的对应物不同，它们不会因相对稳定性较低而导致活性时间相对较短和/或不会导致材料变黄，例如纺织品或聚合物。本发明还涉及一种简单、廉价和环保的制备这些化合物的方法。本发明的磷酸化过程也可以扩展到简单的酚类化合物，只要它们至少有一个可接近的羟基。根据本发明磷酸化的化合物可用作抗氧化剂、自由基清除剂、金属和蛋白质络合剂、抗菌或抗过敏化合物以及用于絮凝纺织品的剂。
• [EN] TOPICAL COMPOSITIONS CONTAINING PHOSPHORYLATED POLYPHENOLS<br/>[FR] COMPOSITIONS TOPIQUES CONTENANT DES POLYPHENOLS PHOSPHORYLES
  申请人：AJINOMOTO OMNICHEM S A

  公开号：WO2006029484A1

  公开（公告）日：2006-03-23

  The present invention provides topical compositions containing phosphorylated polyphenols in combination with a topically acceptable carrier. The compositions of the invention provide a means for delayed delivery of the polyphenol to keratinous tissues, such as skin, hair and nails, with enzymes of the keratinous tissue dephosphorylating the polyphenol, and returning it to its native active form. The compositions are particularly useful in the regulation of skin conditions.

  本发明提供了含有磷酸化多酚的局部组成物，与局部可接受的载体相结合。本发明的组成物提供了一种延迟将多酚传递到角质组织（如皮肤、头发和指甲）的手段，角质组织的酶去磷酸化多酚，并将其返回其原生活性形式。该组成物在调节皮肤状况方面特别有用。
• Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders
  申请人：Amazentis SA

  公开号：US20170143667A1

  公开（公告）日：2017-05-25

  Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

  提供了一些化合物或化合物前体的组合物，可用于各种治疗应用，包括治疗和/或预防与线粒体活性降低或不足有关的疾病或障碍，包括衰老或压力、糖尿病、肥胖症和神经退行性疾病等。这些化合物通常与石榴酸单宁和尿石榴素A等尿石榴素有关。在某些实施例中，这些组合物以食品产品或营养补充剂的形式呈现。这些相同的化合物和组合物也可以在通常健康的个体中有益地用于增加或维持代谢率，减少体脂百分比，增加或维持肌肉质量，管理体重，改善或维持心理表现（包括记忆），改善或维持肌肉表现，改善或维持情绪，以及管理压力。
• COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS
  申请人：Amazentis SA

  公开号：US20170143666A1

  公开（公告）日：2017-05-25

  Provided are compositions comprising compounds or precursors to compounds which may be used for a. variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and uroiithin A. In certain embodiment the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

  提供的是包含化合物或其前体的组合物，可用于各种治疗应用，包括但不限于治疗与线粒体活性降低或不足有关的疾病或紊乱，如衰老或压力、糖尿病、肥胖症和神经退行性疾病。这些化合物通常与石榴酸单宁和尿石榴素A有关。在某些实施例中，这些组合物以食品产品或营养补充剂的形式呈现。这些相同的化合物和组合物也可用于一般健康的人，以增加或维持代谢率，降低身体脂肪百分比，增加或维持肌肉质量，管理体重，改善或维持心理表现（包括记忆），改善或维持肌肉表现，改善或维持情绪，以及管理压力。